Medicine coating rack

A drug coating and drug technology, which can be used in drug combinations, pharmaceutical formulations, medical preparations with inactive ingredients, etc., can solve problems such as stents affecting the efficacy of PTA, avoid the risk of delayed thrombosis, prevent restenosis, Reduces the effect of neointima formation

Inactive Publication Date: 2004-12-08
SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
View PDF0 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, in-stent restenosis has become the main problem and fatal weakness affecting the efficacy of PTA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Add 0.20g of polybutylmethacrylate and 0.20g of ethylene-vinyl acetate copolymer into 10ml of trichloroethane, mix and disperse evenly, then add 0.10g of paclitaxel, disperse evenly at room temperature, and then spray on the surface of the stent. Cured in air for 60min. Repeat the above operation until the drug loading reaches 50 μg / cm 2 . The scaffolds were then dried in a vacuum oven. The mixture of parylene and cilostazol was coated on the outside of the drug-loaded layer by vapor deposition with a thickness of 1 μm.

Embodiment 2

[0023] Add an appropriate amount (eg 0.10g) of polylactic acid (PLA) and 0.10g of polycaprolactone (PCL) into 10ml of trichloroethane, mix and disperse evenly, then add 0.10g of paclitaxel, disperse evenly at room temperature, and then spray on bracket surface. Cured in air for 60min. Repeat the above operations until the drug loading reaches 400 μg / cm 2 . The scaffolds were then dried in a vacuum oven. The mixture of parylene and ticlopidine was coated on the outside of the drug-loaded layer by vapor deposition, and the thickness was controlled at 0.01 μm.

Embodiment 3

[0025] Add appropriate amount such as 0.20g polybutylmethacrylate and 0.20g ethylene-vinyl acetate copolymer to 10ml trichloroethane, mix and disperse evenly, then add 0.075g Cilostazol and 0.10g paclitaxel, disperse evenly under room temperature, then Spray on the surface of the bracket. Cured in air for 30min. Repeat the above operations until the weight of the drug-loaded layer reaches 200 μg / cm 2 . Then the stent was placed in a vacuum oven at 30° C. and vacuumed for 24 hours. In order to prevent the adhesion between the drug coating and the balloon, a layer of Parylene or its derivatives can be coated on the surface of the stent by vapor deposition, with a thickness of 10 microns.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
thicknessaaaaaaaaaa
thicknessaaaaaaaaaa
Login to view more

Abstract

A scaffold with coated medicine layer is composed of scaffold body and medicine layer containing taxol or its derivative, anti-thrombocyte medicine and anti-inflammatory medicine. Its advantages are high effect to durably prevent the new growth of tunica intima, renarrowing and delayed thrombus, and no affection to normal endothelium process.

Description

technical field [0001] The invention relates to a stent provided with drug coating, in particular to a drug-coated stent for preventing / treating post-interventional intimal hyperplasia. The stent coating contains paclitaxel or its derivatives, which can effectively inhibit the formation of angiogenesis intima and the proliferation and migration of smooth muscle cells (SMC), and slowly release the drug to the vascular lesion to prevent restenosis the goal of. Background technique [0002] The stenosis or blockage of the lumen caused by atherosclerosis is the main cause of ischemic heart disease (coronary heart disease), resulting in 500,000 to 600,000 deaths per year. Percutaneous transluminal angioplasty (PTA) uses balloon inflation to dilate occluded or narrowed blood vessels and restore blood supply to normal. Among them, transcutaneous coronary angioplasty (PTCA) has been widely used in the treatment of coronary heart disease. After more than 20 years of development, P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/337A61K31/4365A61K31/573A61K47/30A61M29/00A61P43/00
Inventor 张一罗七一唐智荣张鹰李俊菲
Owner SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap